nivolumab,ipilimumab,cabozantinib
bms,exelixis
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'nct03937219', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'nivo', 'cosmic-313', 'bristol', 'exelixis']
 #gu23 phenomenal presentation by showing maintained pfs benefit with 5 month follow up 
Medical Director of GU Medical Oncology, Assistant Professor @UCSF with focus on #KidneyCancer. Alum of @UChicago. RTs not endorsements